Gastrointestinal Manifestations of Coronavirus Disease-2019 {#sec1}
===========================================================

*A systemic review and meta-analysis showed that SARS-CoV-2 viral RNA was detected in nearly one-half of patients with COVID-19.*

Originating from Wuhan, China, the coronavirus disease-2019 (COVID-19) pandemic has already claimed the lives of more than several hundred thousand individuals worldwide. Infection with sever acute respiratory syndrome coronvirus-2 is characterized by fever and respiratory symptoms, although gastrointestinal symptoms and shedding of viral RNA into feces are common.

In this issue of *Gastroenterology*, Cheung et al performed a systemic review and meta-analysis of gastrointestinal manifestations of COVID-19 and summarized a cohort of COVID-19 patients in Hong Kong. In a meta-analysis of 60 studies including 4243 patients, the pooled prevalence of all gastrointestinal symptoms was 17.6% (95% confidence interval, 12.3%--24.5%). Viral RNA was detected in 48.1% (95% confidence interval, 38.3%--57.9%) of stool samples. Among patients who had both positive respiratory and stool samples, 70.3% (95% confidence interval, 49.6%--85.1%) had persistent stool viral RNA after respiratory samples turned negative. In a cohort of 59 patients in Hong Kong, 15 (25%) had gastrointestinal symptoms and 9 (15%) tested positive for stool viral RNA. Stool viral RNA was detected in 8.7% of those without diarrhea. The study showed that viral RNA was detectable in stool samples in nearly one-half of the patients and remained detectable even after respiratory samples turned negative. These results highlight the importance of exercising caution when handling fecal samples and provide important insights into transmission and control of the virus.

**See page 81.**

Blended Versus Forced Current Coagulation for Polypectomy {#sec3}
=========================================================

*A recent trial found no difference in effectiveness or safety between blended current (yellow) versus coagulation current (blue) during polypectomy.*

Electrosurgical snare resection is the standard approach in resecting large colonic polyps. However, the effectiveness and safety of different electrocautery approaches are unclear. In this issue of *Gastroenterology*, Pohl et al reported a single-blinded, randomized trial to compare blended current (*yellow*) versus coagulation current (*blue*) during polypectomy. Patients undergoing endoscopic mucosal resection of nonpedunculated colorectal polyps of ≥20 mm (n = 928) were randomly assigned to blended current versus coagulation current, as well as clip closure versus no clip closure in a 2 × 2 design.

There were no differences in severe adverse events in the blended current group (7.2%) and coagulation current group (7.9%). The proportions of polyps that were completely removed (96% vs 95%) and proportion of recurrent polyps (17% vs 17%) were also similar among the 2 groups. A total of 17% patients in the blended current group had immediate bleeding requiring intervention, compared with 11% in the coagulation current group (*P* = .006). This study showed that the 2 commonly used electrocautery methods in polypectomy offered similar effectiveness and safety profiles. The choice of electrocautery could, therefore, be an individualized approach based on the preferences and expertise of endoscopists.

**See page 119; editorial on page 32.**

Wheat Consumption, Colitis, and Trypsin Inhibitor-Mediated Dysbiosis {#sec5}
====================================================================

*Amylase trypsin inhibitors, found in wheat, alter intestinal antimicrobial function, decrease anti-inflammatory microbial populations, and increase chemical colitis sensitivity.*

Intriguing parallels exist between the increasing incidence of inflammatory bowel disease and the rise of the typical Western diet, dominated by the presence of wheat and wheat-based components. Furthermore, the rapidity of the increase in inflammatory bowel disease suggests environmental rather than genetic factors as significant contributors. Amylase trypsin inhibitors are nongluten proteins found in wheat that signal through toll-like receptor-4 to activate innate immune responses. In this issue of *Gastroenterology*, Pickert et al investigate further immune-modulating roles of amylase trypsin inhibitors, specifically their ability to modify the gut microbiota. Wild-type mice on a wheat-containing diet had more severe dextran sodium sulfate-induced colitis in association with increased permeability and IL-17, IL-6, and tumor necrosis factor-α levels. Furthermore, these mice had decreased diversity in the intestinal microbiota and expansion of noncommensal species.

Antibiotic therapy protected from wheat-induced colitis susceptibility, consistent with earlier literature documenting a microbiota requirement for dextran sodium sulfate injury; however, stool from wheat-fed mice transplanted into antibiotic-treated recipients was sufficient to restore colitis susceptibility, highlighting the critical requirements for wheat-conditioned microbiota. Further experiments determined that amylase trypsin inhibitor administration affected Paneth and goblet cell antimicrobial gene expression, decreased microbial diversity, and decreased \"anti-inflammatory\" microbial species while increasing colitis-sensitizing species and reproduced whole-wheat dextran sodium sulfate colitogenic effects. These exciting findings link changes in diet with intestinal epithelial function, microbial dysbiosis, and susceptibility to experimental colitis. Whether these findings similarly affect the development of or susceptibility to inflammatory bowel disease in humans, fed a diet with much greater complexity, will need to be studied.

**See page 256.**

CPEB4-Induced Expression of PFKFB3 Promotes Liver Fibrosis {#sec6}
==========================================================

*Metabolic reprogramming of hepatic stellate cells into myofibroblasts occurs via post-transcriptional up-regulation of key glycolytic regulatory enzyme, PFKFB3. Small molecule inhibitor targeting of PFKB3 decreases fibrosis in murine models.*

Hepatic injury responses initiate with activation and transdifferentiation of resident quiescent hepatic stellate cells (HSCs), resulting in the deposition of extracellular matrix to preserve organ structural integrity. Upon recovery, this response is suppressed; however, in the case of persistent injury, it remains active, leading to parenchymal dysfunction and fibrosis. Previous studies have determined that HSC activation phenotypically shifts HSCs to aerobic glycolysis, yet the mechanisms regulating this process are not understood.

In this issue of *Gastroenterology*, Mejias et al attempt to determine the regulatory mechanisms governing HSC adaptions during chronic liver injury. Cultured murine HSCs transdifferentiated into myofibroblastic subtypes exhibited increased 6-phosphofructo2-kinase/fructose 2,6-bisphosphatase-3 (PFKFB3) expression. PFKFB3 drives glycolysis, and its metabolite, fructose2,6-bisphosphate (F2,6BP), activates rate-limiting phosphofructokinase-1. Inhibiting PFKFB3 using the small molecule inhibitor 3PO decreased F2,6BP and HSC transdifferentiation as evidenced by morphologic analysis and reduction in the myofibroblastic marker alpha-smooth muscle actin. In support of these observations\' clinical relevance, PFKFB3 was increased in both human and experimentally induced rodent fibrotic livers. Furthermore, 3PO therapy decreased rodent bile duct ligation-induced liver fibrosis, providing experimental evidence to support a critical role for PFKFB3 in fibrosis.

From a molecular standpoint, the RNA binding protein CPEB4 increases during hepatic injury, augments PFKFB3 expression via post-transcriptional regulation, and is required for PFKFB3-induced liver fibrosis in murine models ([Figure 3](#fig3){ref-type="fig"} ). This impactful work identifies a novel metabolic pathway reprogramming HSCs to myofibroblastic phenotypes, a potential therapeutic target, and a small-molecule inhibitor with clinical potential in preventing or treating patients with chronic liver disease.Figure 1Gastrointestinal symptoms and stool viral RNA positivity rate in patients with coronavirus disease-2019 (COVID-19). CI, confidence interval.Figure 2Electrocautery setting for polyp resection. RCT, randomized, controlled trial.Figure 3Graphical abstract from Mejias et al.

**See page 272.**
